Strumento inattivo

Altre lingue Alzheon, Inc.

Azioni

ALZH

US00168L1017

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Alzheon, Inc. Announces Two Peer-Reviewed Scientific Publications Describe Fluid Biomarker, Brain Preservation and Clinical Benefits Following 2 Years of Treatment in Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer's Disease	25/06
Alzheon, Inc Announces Appointment of Gino Santini to Board of Directors	12/06
Alzheon, Inc. announced that it has received $100 million in funding	12/06
Alzheon, Inc. Announces First Patient Dosed in Long-Term Extension of APOLLOE4 Phase 3 Trial of Oral ALZ-801/Valiltramiprosate and Launches 52-Week Extension of Phase 2 Biomarker Trial in Patients with Early Alzheimer's Disease	30/04
Alzheon, Inc. announced a financing transaction	27/02
Alzheon Promotes Glenn E. Pauly to Chief Commercial Officer	05/12
Alzheon, Inc. to Present Biomarker, Brain Preservation, and Clinical Results from Pivotal Program of Oral ALZ-801/Valiltramiprosate at 16th Annual Clinical Trials in Alzheimer's Disease Conference	17/10/23
Alzheon To Present Pivotal Program of Oral ALZ-801/Valiltramiprosate at Singularity Conference, Goldman Sachs Alzheimer?s Disease Day, and BIO Investor Forum	26/09/23
Alzheon Reports Biomarker, Brain Preservation and Clinical Benefits Following 24 Months of Treatment in Phase 2 Trial of Oral ALZ-801 in Patients with Early Alzheimer's Disease	13/09/23
Alzheon to Present Baseline Imaging Characteristics from Ongoing APOLLOE4 Phase 3 Trial of Oral Tablet	11/07/23
Alzheon, Inc. to Present Baseline Imaging Characteristics from Ongoing APOLLOE4 Phase 3 Trial of Oral Tablet ALZ-801 (Valiltramiprosate) and Results of Phase 2 Biomarker Study At American Academy of Neurology Conference in Boston	18/04/23
Alzheon, IncAnnounces Early Completion of Enrollment of APOLLOE4 Phase 3 Clinical Trial Evaluating Oral ALZ-801 (Valiltramiprosate) in APOE4/4 Homozygotes with Early Alzheimer’s Disease	06/12/22
Alzheon, Inc. announced that it expects to receive $50.004201 million in funding	30/11/22
Alzheon, Inc. Reports Brain Preservation and Clinical Effects Following 12 Months of Treatment in Phase 2 Trial of Oral Alz-801 (Valiltramiprosate) in Patients with Early Alzheimer’S Disease	20/09/22
Alzheon, Inc Appoints Glenn Pauly as Head of Commercial	20/09/22
Alzheon, Inc. to Present Industry-Leading Phase 2 Biomarker and Clinical Data with ALZ -801 (Valiltramiprosate) Oral Tablet At 2022 Alzheimer’S Association International Conference	26/07/22
Alzheon, Inc. announced that it has received $50.000004 million in funding	14/04/22
Alzheon to Present ALZ-801 (Valiltramiprosate) Phase 3 Program Update and Industry-Leading Disease Modifying Effects from Phase 2 Trial in Patients with Early Alzheimer’s Disease At AD/PD and NDDS Scientific Conferences	08/03/22
Alzheon Reports Disease Modifying Effects from Phase 2 Biomarker Trial of Oral Tablet ALZ-801 (Valiltramiprosate) in Patients with Early Alzheimer’s Disease	08/02/22
Alzheon to Present New Data from Ongoing Phase 2 Biomarker Trial of ALZ-801 Oral Tablet at Clinical Trials in Alzheimer?s Disease Conference	01/11/21

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Alzheon, Inc.

Azioni

ALZH

US00168L1017

Altre lingue

Filtri